Edaravone Combined with Xueshuantong in Treatment of Acute Cerebral Infarction:A Systematic Review and Meta Analysis

Li Liqun; Li Chunming; Zhao Haolin; Huang Yu; Wei Wei

doi:10.3969/j.issn.1672-1349.2015.14.006

Abstract：Objective To assess the clinical efficacy and safety of edaravone and Xueshuantong in treatment of acute cerebral infarc-tion by conducting a meta analysis of randomized or quasi control ed trails.Methods The CNKI,Wan Fang Database,VIP and CBM and PubMed were searched to col ect clinical trails of edaravone and Xueshuantong in treatment of acute cerebral infarction that were published from the beginning the databases to January 2014,then assessed the methodological quality with the method in the Co-chrane handbook and then made a Meta analysis with the Review Manage 5.1 software.Results Our study adopted 24 studies,2 204 participants were included in total.Only one of the included studies had moderate quality,and 16 studies described side effect.This meta analysis showed that edaravone and Xueshuantong can improve the total effective rate,curative rate,neurological function and activities of daily living of the acute cerebral infarction with statistical significance respectively[OR=4.03,95% CI (3.09,5.25)], [OR=2.07,95% CI (1.68,2.55)],[OR=8.48,95% CI (6.292,10.68)],[OR=6.46,95% CI (4.82,8.10)],[OR=5.03,95% CI (3.67,6.38)],[OR=9.79,95% CI (6.69,12.89)].However,there was not statistical significance on the improving of high sensitivity C reactive protein (hs CRP)[OR=23.00,95% CI (-18.41,64.40)].Conclusion The current evidences show that edaravone combined Xueshuantong is more effective on the total effective rate,curative rate,neurological function and activities of daily living with safety.However,more high quality studies with large scales and long term fol ow up are stil needed to verify the above con-clusion in the future studies because of the limitations of the included studies.